Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
91 participants
Study Classification
INTERVENTIONAL
Study Start Date
2015-02-25
Study Completion Date
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this trial is to establish the safety and feasibility of the Edwards SAPIEN XT™and SAPIEN 3™ device and delivery systems in patients with severe symptomatic calcific mitral valve disease with severe mitral annular calcification who are not candidates for standard mitral valve surgery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - High Risk and Nested Registry 7
NCT03222141
Symptomatic Severe Aortic Stenosis
COMPLETED
NA
ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral
NCT06167213
Mitral Regurgitation
Mitral Valve Disease
Mitral Stenosis
NOT_YET_RECRUITING
NA
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve
NCT03225001
Aortic Stenosis
Cardiomyopathy, Hypertrophic
COMPLETED
NA
PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
NCT02675114
Aortic Stenosis
ACTIVE_NOT_RECRUITING
NA
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - S3 Intermediate
NCT03222128
Symptomatic Severe Aortic Stenosis
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Design:
A prospective pilot study enrolling extremely high surgical risk patients with symptomatic severe calcific mitral valve disease undergoing implantation of an Edwards Sapien XT or SAPIEN 3 valve in the mitral position.
There are three arms in this study evaluating three separate patient populations described below:
* Native Mitral Valve with severe Mitral Annular Calcification (MAC): Patients with symptomatic severe disease of a native mitral valve due to severe mitral annular calcification.
* Valve-in-Ring: Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis.
* Valve-in-Valve: Patients with failing bioprosthetic surgical valves with severe regurgitation or stenosis
The delivery approaches include: standard transeptal, modified transeptal approach with a guidewire externalized through a sheath percutaneously placed in the left ventricle, surgical trasnapical and surgical transatrial delivery approach with or without surgical resection of the anterior mitral valve (MV) leaflet (in the native mitral valve arm).
The MITRAL Trial site investigative team (heart team) consists of dedicated representatives from cardiac surgery, interventional cardiology, echocardiology, neurology, study coordination and other multi-disciplinary team members consistent with a transcatheter aortic valve replacement (TAVR) model.
Endpoints
Most endpoints were defined following the Mitral Valve Academic Research Consortium (MVARC) recommendations with minor modifications.73
The primary safety endpoint is: technical success at exit from the cath lab
• Technical success (at exit from the cath lab) is defined as:
* Successful vascular and/or TA access, delivery and retrieval of the transcatheter valve delivery system
* Deployment of a single valve
* Correct position of transcatheter valve in the mitral annulus
* Adequate performance of the prosthetic heart valve (mean mitral valve gradient (MVG) \<10 mmHg) without residual mitral regurgitation (MR) grade ≥2 (+)
* No need for additional surgery or re-intervention (includes drainage of pericardial effusion)
* The patient leaves the cath lab alive
The primary performance endpoint is: absence of MR grade 2 (+) or greater or mean MVG ≥10 mmHg at 30 days and 1 year.
Secondary safety endpoints include: Procedural success and all -cause mortality at 30 days and 1 year.
* Procedural Success (30 days) in defined as:
* Device success at 30 days
* No device/procedure related severe adverse event (SAE's) including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.
* Device success is defined as:
* Stroke free survival with original valve in place
* No need for additional surgery or re-intervention related to the procedure, access or to the replacement valve
* Proper placement and intended function of the replacement valve, including
* No migration, fracture, thrombosis, hemolysis or endocarditis
* No replacement valve stenosis (MV gradient \< 10 mmHg)
* Replacement valve regurgitation \< 2 + (including central and paravalvular leak) and without associated hemolysis
* No increase in AI from baseline (more than 1 grade) and LVOT gradient \< 20 mmHg increase from baseline
Additional secondary safety and effectiveness endpoints will be evaluated at two time points: (1) acute, covering events occurring out to 30 days or hospital discharge, whichever is longer; and (2) longer-term, covering events from 31 days to 1 year, and include the following:
Additional Safety Endpoints:
Freedom from
* all stroke and TIA (MVARC)
* myocardial infarction
* major vascular complication (MVARC)
* life-threatening bleeding (MVARC)
* mitral valve reoperation or catheter-based intervention for: valve thrombosis, valve displacement, or other valve placed procedure-related complication
* hemolysis
* endocarditis
* moderate or severe central mitral insufficiency ≥ 2 (+), and/or moderate or severe perivalvular leak causing ≥ 2 (+) mitral insufficiency
* significant mitral stenosis (mean MVG \>10 mmHg)
* new permanent pacemaker insertion
* new aortic valve dysfunction (difference greater than 1(+) severity compared with baseline)
* new LVOT gradient ≥ 20 mmHg, or ≥ 20 mmHg increase from baseline LVOT gradient.
* acute kidney injury (MVARC)
* new onset atrial fibrillation
* blood transfusion
* access site infection
* need for iatrogenic ASD closure after index procedure
Additional Effectiveness Endpoints:
1. Rehospitalization at 1 year and Total days alive and out of hospital (from date of index procedure)
2. Clinical improvement per NYHA Class (from baseline) by at least 1 class.
3. Clinical improvement per Quality of Life instruments (\>10 points from baseline): (KCCQ 12) (Appendix N)
4. Clinical improvement per 6 Minute Walk Test (\> 50 meters from baseline) and 5 meter walk test. (Appendix H)
5. Mean ICU and total index procedure hospital length of stay
Additional Valve Performance Endpoints:
1. Freedom from major mitral paravalvular leak
2. Improvement in hemodynamic function: mean gradient
3. Freedom from structural valve deterioration
4. Total mitral regurgitation
A prospective pilot study enrolling extremely high surgical risk patients with symptomatic severe calcific mitral valve disease undergoing implantation of an Edwards Sapien XT or SAPIEN 3 valve in the mitral position.
There are three arms in this study evaluating three separate patient populations described below:
* Native Mitral Valve with severe Mitral Annular Calcification (MAC): Patients with symptomatic severe disease of a native mitral valve due to severe mitral annular calcification.
* Valve-in-Ring: Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis.
* Valve-in-Valve: Patients with failing bioprosthetic surgical valves with severe regurgitation or stenosis
The delivery approaches include: standard transeptal, modified transeptal approach with a guidewire externalized through a sheath percutaneously placed in the left ventricle, surgical trasnapical and surgical transatrial delivery approach with or without surgical resection of the anterior mitral valve (MV) leaflet (in the native mitral valve arm).
The MITRAL Trial site investigative team (heart team) consists of dedicated representatives from cardiac surgery, interventional cardiology, echocardiology, neurology, study coordination and other multi-disciplinary team members consistent with a transcatheter aortic valve replacement (TAVR) model.
Endpoints
Most endpoints were defined following the Mitral Valve Academic Research Consortium (MVARC) recommendations with minor modifications.73
The primary safety endpoint is: technical success at exit from the cath lab
• Technical success (at exit from the cath lab) is defined as:
* Successful vascular and/or TA access, delivery and retrieval of the transcatheter valve delivery system
* Deployment of a single valve
* Correct position of transcatheter valve in the mitral annulus
* Adequate performance of the prosthetic heart valve (mean mitral valve gradient (MVG) \<10 mmHg) without residual mitral regurgitation (MR) grade ≥2 (+)
* No need for additional surgery or re-intervention (includes drainage of pericardial effusion)
* The patient leaves the cath lab alive
The primary performance endpoint is: absence of MR grade 2 (+) or greater or mean MVG ≥10 mmHg at 30 days and 1 year.
Secondary safety endpoints include: Procedural success and all -cause mortality at 30 days and 1 year.
* Procedural Success (30 days) in defined as:
* Device success at 30 days
* No device/procedure related severe adverse event (SAE's) including: death, stroke, MI or coronary ischemia requiring PCI or CABG, stage 2 or 3 AKI including dialysis, life threatening bleeding, major vascular or access complications (arterial, venous, or TA - any event requiring additional unplanned surgical or transcatheter intervention), pericardial effusion or tamponade requiring drainage, severe hypotension, heart failure or respiratory failure requiring intravenous pressors or invasive or mechanical treatments such as ultrafiltration or hemodynamic assist devices including intra-aortic balloon pump or left ventricular assist device, or prolonged intubation for ≥48 hrs, or any valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention.
* Device success is defined as:
* Stroke free survival with original valve in place
* No need for additional surgery or re-intervention related to the procedure, access or to the replacement valve
* Proper placement and intended function of the replacement valve, including
* No migration, fracture, thrombosis, hemolysis or endocarditis
* No replacement valve stenosis (MV gradient \< 10 mmHg)
* Replacement valve regurgitation \< 2 + (including central and paravalvular leak) and without associated hemolysis
* No increase in AI from baseline (more than 1 grade) and LVOT gradient \< 20 mmHg increase from baseline
Additional secondary safety and effectiveness endpoints will be evaluated at two time points: (1) acute, covering events occurring out to 30 days or hospital discharge, whichever is longer; and (2) longer-term, covering events from 31 days to 1 year, and include the following:
Additional Safety Endpoints:
Freedom from
* all stroke and TIA (MVARC)
* myocardial infarction
* major vascular complication (MVARC)
* life-threatening bleeding (MVARC)
* mitral valve reoperation or catheter-based intervention for: valve thrombosis, valve displacement, or other valve placed procedure-related complication
* hemolysis
* endocarditis
* moderate or severe central mitral insufficiency ≥ 2 (+), and/or moderate or severe perivalvular leak causing ≥ 2 (+) mitral insufficiency
* significant mitral stenosis (mean MVG \>10 mmHg)
* new permanent pacemaker insertion
* new aortic valve dysfunction (difference greater than 1(+) severity compared with baseline)
* new LVOT gradient ≥ 20 mmHg, or ≥ 20 mmHg increase from baseline LVOT gradient.
* acute kidney injury (MVARC)
* new onset atrial fibrillation
* blood transfusion
* access site infection
* need for iatrogenic ASD closure after index procedure
Additional Effectiveness Endpoints:
1. Rehospitalization at 1 year and Total days alive and out of hospital (from date of index procedure)
2. Clinical improvement per NYHA Class (from baseline) by at least 1 class.
3. Clinical improvement per Quality of Life instruments (\>10 points from baseline): (KCCQ 12) (Appendix N)
4. Clinical improvement per 6 Minute Walk Test (\> 50 meters from baseline) and 5 meter walk test. (Appendix H)
5. Mean ICU and total index procedure hospital length of stay
Additional Valve Performance Endpoints:
1. Freedom from major mitral paravalvular leak
2. Improvement in hemodynamic function: mean gradient
3. Freedom from structural valve deterioration
4. Total mitral regurgitation
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Mitral Valve Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Native mitral valve with severe MAC
Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
Group Type
EXPERIMENTAL
Transcatheter Mitral Valve Replacement
Intervention Type
DEVICE
Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
Valve-in-Ring
Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
Group Type
EXPERIMENTAL
Transcatheter Mitral Valve Replacement
Intervention Type
DEVICE
Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
Valve-in-Valve
Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
Group Type
EXPERIMENTAL
Transcatheter Mitral Valve Replacement
Intervention Type
DEVICE
Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcatheter Mitral Valve Replacement
Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
All Candidates must meet the following criteria:
1. Patient has severe calcific native mitral valve stenosis with mitral annular calcification with echocardiographically derived mitral valve area (MVA) of ≤1.5 cm2, or severe mitral regurgitation with severe mitral annular calcification and at least moderate mitral valve stenosis. Qualifying echo must be within 60 days of the date of the procedure.
2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater, or symptoms during stress test.
3. The patient is at least 22 years old.
4. The heart team agrees (and verified in the case review process) that valve implantation will likely benefit the patient.
5. The heart team agrees that medical factors preclude operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. Specifically, the STS score is ≥15% or the probability of death or serious, irreversible morbidity is ≥ 50%. The surgeons' consult notes shall specify the medical or anatomic factors leading to that conclusion and include a printout of the calculation of the STS score to additionally identify the risks in the patient (some medical factors and definitions are provided below). At least one of the cardiac surgeon assessors must have physically evaluated the patient. All patients must be approved by the Patient Selection and Procedure Management Steering Committee (at least 2 member votes, one must be a cardiac surgeon).
6. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
7. The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which will be conducted as a phone follow-up.
All Candidates must meet the following criteria:
1. Patient has a failing surgical ring in the mitral position with severe mitral regurgitation or stenosis (echocardiographically derived mitral valve area \[MVA\] of ≤1.5 cm2. Qualifying echo must be within 60 days of the date of the procedure.
2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater, or symptoms during stress test, or severe hemolytic anemia requiring blood transfusions and no other cause of hemolytic anemia is found after extensive work up.
All Candidates must meet the following criteria:
1. Patient has a failing surgical bioprosthesis in the mitral position with severe mitral regurgitation or stenosis with echocardiographically derived mitral valve area (MVA) of ≤1.5 cm2. Qualifying echo must be within 60 days of the date of the procedure.
2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater, or symptoms during stress test.
1. Patient has severe calcific native mitral valve stenosis with mitral annular calcification with echocardiographically derived mitral valve area (MVA) of ≤1.5 cm2, or severe mitral regurgitation with severe mitral annular calcification and at least moderate mitral valve stenosis. Qualifying echo must be within 60 days of the date of the procedure.
2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater, or symptoms during stress test.
3. The patient is at least 22 years old.
4. The heart team agrees (and verified in the case review process) that valve implantation will likely benefit the patient.
5. The heart team agrees that medical factors preclude operation, based on a conclusion that the probability of death or serious, irreversible morbidity exceeds the probability of meaningful improvement. Specifically, the STS score is ≥15% or the probability of death or serious, irreversible morbidity is ≥ 50%. The surgeons' consult notes shall specify the medical or anatomic factors leading to that conclusion and include a printout of the calculation of the STS score to additionally identify the risks in the patient (some medical factors and definitions are provided below). At least one of the cardiac surgeon assessors must have physically evaluated the patient. All patients must be approved by the Patient Selection and Procedure Management Steering Committee (at least 2 member votes, one must be a cardiac surgeon).
6. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
7. The study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which will be conducted as a phone follow-up.
All Candidates must meet the following criteria:
1. Patient has a failing surgical ring in the mitral position with severe mitral regurgitation or stenosis (echocardiographically derived mitral valve area \[MVA\] of ≤1.5 cm2. Qualifying echo must be within 60 days of the date of the procedure.
2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater, or symptoms during stress test, or severe hemolytic anemia requiring blood transfusions and no other cause of hemolytic anemia is found after extensive work up.
All Candidates must meet the following criteria:
1. Patient has a failing surgical bioprosthesis in the mitral position with severe mitral regurgitation or stenosis with echocardiographically derived mitral valve area (MVA) of ≤1.5 cm2. Qualifying echo must be within 60 days of the date of the procedure.
2. Patient is symptomatic from mitral valve disease, as demonstrated by reported NYHA Functional Class II or greater, or symptoms during stress test.
Exclusion Criteria
Candidates will be excluded from the study if any of the following conditions are present:
1. Heart Team assessment of operability (the heart team considers the patient is a surgical candidate).
2. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment \[defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)\].
3. Mitral annulus is not calcified (only applies to patients included in Native MV arm).
4. Complex untreated coronary artery disease:
1. Unprotected left main coronary artery
2. Syntax score \> 32 (in the absence of prior revascularization)
5. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker is not excluded.
6. Any patient with a balloon valvuloplasty (BMV) within 30 days of the procedure (unless BMV is a bridge to procedure after a qualifying ECHO).
7. Patients with planned concomitant surgical or transcatheter ablation for Atrial Fibrillation.
8. Leukopenia (WBC \< 3000 cell/mL), acute anemia (Hgb \< 9 g/dL), Thrombocytopenia (Plt \< 50,000 cell/mL).
9. Hypertrophic obstructive cardiomyopathy (HOCM).
10. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation.
11. Need for emergency surgery for any reason.
12. Severe ventricular dysfunction with LVEF \< 20%.
13. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
14. Active upper GI bleeding within 3 months (90 days) prior to procedure.
15. A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.
16. For patients enrolled in the Native MV arm: Native mitral annulus size \< 275 mm2 or \> 740 mm2 as measured by CT scan.
For patients in Valve-in-Ring arm: surgical ring with a true mean internal diameter ≤18 mm or ≥ 29 mm or an area \< 275 mm2 or \> 740 mm2 as measured by CT scan. Caution recommended in:
* Incomplete bands due to risk of paravalvular leak and risk of LVOT obstruction. Careful measurements by CT and CT-guided procedural planning is recommended.
* Non-circular rigid or semi-flexible rings (e.g., D-shaped, saddle shaped, etc) due to risk of para-valvular leak and/or out of round or incomplete valve expansion.
For patients in Valve-in-Valve arm: surgical bioprosthesis with a true internal diameter ≤18 mm or ≥ 29 mm
17. Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 6 months (180 days) of the procedure.
18. Estimated life expectancy \< 24 months (730 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease.
19. Expectation that patient will not improve despite treatment of mitral stenosis
20. Active bacterial endocarditis within 6 months (180 days) of procedure.
1. Heart Team assessment of operability (the heart team considers the patient is a surgical candidate).
2. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment \[defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)\].
3. Mitral annulus is not calcified (only applies to patients included in Native MV arm).
4. Complex untreated coronary artery disease:
1. Unprotected left main coronary artery
2. Syntax score \> 32 (in the absence of prior revascularization)
5. Any therapeutic invasive cardiac procedure resulting in a permanent implant that is performed within 30 days of the index procedure (unless part of planned strategy for treatment of concomitant coronary artery disease). Implantation of a permanent pacemaker is not excluded.
6. Any patient with a balloon valvuloplasty (BMV) within 30 days of the procedure (unless BMV is a bridge to procedure after a qualifying ECHO).
7. Patients with planned concomitant surgical or transcatheter ablation for Atrial Fibrillation.
8. Leukopenia (WBC \< 3000 cell/mL), acute anemia (Hgb \< 9 g/dL), Thrombocytopenia (Plt \< 50,000 cell/mL).
9. Hypertrophic obstructive cardiomyopathy (HOCM).
10. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of screening evaluation.
11. Need for emergency surgery for any reason.
12. Severe ventricular dysfunction with LVEF \< 20%.
13. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
14. Active upper GI bleeding within 3 months (90 days) prior to procedure.
15. A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.
16. For patients enrolled in the Native MV arm: Native mitral annulus size \< 275 mm2 or \> 740 mm2 as measured by CT scan.
For patients in Valve-in-Ring arm: surgical ring with a true mean internal diameter ≤18 mm or ≥ 29 mm or an area \< 275 mm2 or \> 740 mm2 as measured by CT scan. Caution recommended in:
* Incomplete bands due to risk of paravalvular leak and risk of LVOT obstruction. Careful measurements by CT and CT-guided procedural planning is recommended.
* Non-circular rigid or semi-flexible rings (e.g., D-shaped, saddle shaped, etc) due to risk of para-valvular leak and/or out of round or incomplete valve expansion.
For patients in Valve-in-Valve arm: surgical bioprosthesis with a true internal diameter ≤18 mm or ≥ 29 mm
17. Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic attack (TIA) within 6 months (180 days) of the procedure.
18. Estimated life expectancy \< 24 months (730 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease.
19. Expectation that patient will not improve despite treatment of mitral stenosis
20. Active bacterial endocarditis within 6 months (180 days) of procedure.
Minimum Eligible Age
22 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henry Ford Hospital
OTHER
Sponsor Role
collaborator
Mayra Guerrero
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mayra Guerrero
Principal Investigator
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mayra E. Guerrero, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner University Medical Center
Phoenix, Arizona, United States
Site Status
Cedars-Sinai Medical Center
Los Angeles, California, United States
Site Status
MedStar Washington Medical Center
Washington D.C., District of Columbia, United States
Site Status
Piedmont HealtCare
Atlanta, Georgia, United States
Site Status
Evanston Hospital / North Shore University HealthSystem
Evanston, Illinois, United States
Site Status
Massachusetts General Hospital
Boston, Massachusetts, United States
Site Status
Brigham and Women's Hospital
Boston, Massachusetts, United States
Site Status
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Site Status
Henry Ford Hospital
Detroit, Michigan, United States
Site Status
Mayo Clinic
Rochester, Minnesota, United States
Site Status
Mount Sinai Hospital
New York, New York, United States
Site Status
Columbia University Medical Center
New York, New York, United States
Site Status
Memorial Hermann Texas Medical Center
Houston, Texas, United States
Site Status
Intermountain Medical Center
Murray, Utah, United States
Site Status
University of Washington Medical Center
Seattle, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Guerrero M, Greenbaum A, O'Neill W. First in human percutaneous implantation of a balloon expandable transcatheter heart valve in a severely stenosed native mitral valve. Catheter Cardiovasc Interv. 2014 Jun 1;83(7):E287-91. doi: 10.1002/ccd.25441. Epub 2014 Mar 14.
Reference Type
BACKGROUND
Sinning JM, Mellert F, Schiller W, Welz A, Nickenig G, Hammerstingl C. Transcatheter mitral valve replacement using a balloon-expandable prosthesis in a patient with calcified native mitral valve stenosis. Eur Heart J. 2013 Sep;34(33):2609. doi: 10.1093/eurheartj/eht254. Epub 2013 Jul 4. No abstract available.
Reference Type
BACKGROUND
Hasan R, Mahadevan VS, Schneider H, Clarke B. First in human transapical implantation of an inverted transcatheter aortic valve prosthesis to treat native mitral valve stenosis. Circulation. 2013 Aug 6;128(6):e74-6. doi: 10.1161/CIRCULATIONAHA.113.001466. No abstract available.
Reference Type
BACKGROUND
Fassa AA, Himbert D, Brochet E, Depoix JP, Cheong AP, Alkhoder S, Nataf P, Vahanian A. Transseptal transcatheter mitral valve implantation for severely calcified mitral stenosis. JACC Cardiovasc Interv. 2014 Jun;7(6):696-7. doi: 10.1016/j.jcin.2013.12.204. Epub 2014 May 14. No abstract available.
Reference Type
BACKGROUND
Ribeiro HB, Doyle D, Urena M, Allende R, Amat-Santos I, Pasian S, Bilodeau S, Mohammadi S, Paradis JM, DeLarochelliere R, Rodes-Cabau J, Dumont E. Transapical mitral implantation of a balloon-expandable valve in native mitral valve stenosis in a patient with previous transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2014 Oct;7(10):e137-9. doi: 10.1016/j.jcin.2014.02.024. Epub 2014 Sep 17. No abstract available.
Reference Type
BACKGROUND
Ferrari E, Niclauss L, Locca D, Marcucci C. On-pump fibrillating heart mitral valve replacement with the SAPIEN XT transcatheter heart valve. Eur J Cardiothorac Surg. 2014 Apr;45(4):749-51. doi: 10.1093/ejcts/ezt364. Epub 2013 Jul 11.
Reference Type
BACKGROUND
Himbert D, Bouleti C, Iung B, Nejjari M, Brochet E, Depoix JP, Ghodbane W, Fassa AA, Nataf P, Vahanian A. Transcatheter valve replacement in patients with severe mitral valve disease and annular calcification. J Am Coll Cardiol. 2014 Dec 16;64(23):2557-8. doi: 10.1016/j.jacc.2014.09.047. No abstract available.
Reference Type
BACKGROUND
Guerrero M, Wang DD, Eleid MF, Pursnani A, Salinger M, Russell HM, Kodali SK, George I, Bapat VN, Dangas GD, Tang GHL, Inglesis I, Meduri CU, Palacios I, Reisman M, Whisenant BK, Jermihov A, Kaptzan T, Lewis BR, Tommaso C, Krause P, Thaden J, Oh JK, Douglas PS, Hahn RT, Leon MB, Rihal CS, Feldman T, O'Neill WW. Prospective Study of TMVR Using Balloon-Expandable Aortic Transcatheter Valves in MAC: MITRAL Trial 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):830-845. doi: 10.1016/j.jcin.2021.01.052.
Reference Type
RESULT
Guerrero M, Wang DD, Pursnani A, Salinger M, Russell HM, Eleid M, Chakravarty T, Ng MH, Kodali SK, Meduri CU, Pershad A, Satler L, Waksman R, Palacios I, Smalling R, Reisman M, Gegenhuber M, Kaptzan T, Lewis B, Tommaso C, Krause P, Thaden J, Oh J, Douglas PS, Hahn RT, Kar S, Makkar R, Leon MB, Feldman T, Rihal C, O'Neill WW. Prospective Evaluation of TMVR for Failed Surgical Annuloplasty Rings: MITRAL Trial Valve-in-Ring Arm 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):846-858. doi: 10.1016/j.jcin.2021.01.051.
Reference Type
RESULT
Guerrero M, Pursnani A, Narang A, Salinger M, Wang DD, Eleid M, Kodali SK, George I, Satler L, Waksman R, Meduri CU, Rajagopal V, Inglessis I, Palacios I, Reisman M, Eng MH, Russell HM, Pershad A, Fang K, Kar S, Makkar R, Saucedo J, Pearson P, Bokhary U, Kaptzan T, Lewis B, Tommaso C, Krause P, Thaden J, Oh J, Lang RM, Hahn RT, Leon MB, O'Neill WW, Feldman T, Rihal C. Prospective Evaluation of Transseptal TMVR for Failed Surgical Bioprostheses: MITRAL Trial Valve-in-Valve Arm 1-Year Outcomes. JACC Cardiovasc Interv. 2021 Apr 26;14(8):859-872. doi: 10.1016/j.jcin.2021.02.027.
Reference Type
RESULT
Guerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, Palacios I, Russell H, Makkar RR, Kar S, Satler LF, Rajagopal V, Dangas G, Tang GHL, McCabe JM, Whisenant BK, Fang K, Balan P, Smalling R, Kaptzan T, Lewis B, Douglas PS, Hahn RT, Thaden J, Oh JK, Leon M, O'Neill W, Rihal C. 5-Year Prospective Evaluation of Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Outcomes: MITRAL Trial Final Results. JACC Cardiovasc Interv. 2023 Sep 25;16(18):2211-2227. doi: 10.1016/j.jcin.2023.06.041.
Reference Type
RESULT
Sticchi A, Reineke D, Praz F, Windecker S. Transcatheter Mitral Valve Replacement for Mitral Valve-in-Valve, Valve-in-Ring, and Valve-in-MAC Using Balloon-Expandable Transcatheter Heart Valves. JACC Cardiovasc Interv. 2021 Apr 26;14(8):873-878. doi: 10.1016/j.jcin.2021.02.034. No abstract available.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
https://www.mayo.edu/research/clinical-trials
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18-006601
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
PARTNER 3 Trial - Aortic Valve-in-Valve
NCT03003299
RECRUITING
NA
The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B
NCT02184442
COMPLETED
NA
THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial
NCT00530894
COMPLETED
NA
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973
RECRUITING
NA
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - XT Intermediate and High Risk
NCT01314313
COMPLETED
NA
PREVAIL-TF: Transfemoral Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)
NCT00820599
COMPLETED
NA
Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 Study
NCT01808287
COMPLETED
NA
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
NCT05172960
ACTIVE_NOT_RECRUITING
NA
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250
ACTIVE_NOT_RECRUITING
NA
PREVAIL-TA: Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Europe)
NCT01238835
COMPLETED
NA
Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis.
NCT03011346
COMPLETED
NA
COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction
NCT02987387
COMPLETED
The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis
NCT03471065
COMPLETED
NA
SOURCE 3: Observational Study to Evaluate Safety and Performance of SAPIEN 3 THV System in Real Life Practice
NCT02698956
COMPLETED
A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease
NCT02100722
ACTIVE_NOT_RECRUITING
NA
PREVAIL-J - Transfemoral & Transapical Placement of Aortic Balloon Expandable Transcatheter Valves Trial (Japan)
NCT01113983
COMPLETED
NA
SOURCE XT REGISTRY
NCT01238497
COMPLETED
A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device
NCT01721642
COMPLETED
PHASE1/PHASE2
ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis (2011-03)
NCT03752996
COMPLETED
NA
ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis
NCT03517436
ACTIVE_NOT_RECRUITING
NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
NCT04889872
RECRUITING
NA
DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI
NCT02070731
COMPLETED
NA
PARTNER II Trial: S3iCAP
NCT02687035
COMPLETED
NA
Prospective Evaluation for Receiving SynFlow 3.0 Interventional Circulatory Support in High-risk PCI: A Randomized Controlled Trial
NCT06853470
COMPLETED
NA
Randomized Sizing and Hemodynamic Study Mitroflow vs. Magna
NCT00705913
TERMINATED
NA